MaaT Pharma Phase III microbiome trial hits endpoints as stock soar

cafead

Administrator
Staff member
  • cafead   Jan 09, 2025 at 11:22: AM
via French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company’s stock price.

article source